Work Here?
Overview
Curie.Bio helps founders discover and develop important new medicines by investing in existing biotech companies, creating focused spinouts, and building ventures from scratch. It deploys about $1B for seed and Series A rounds and works closely with a 100-person team that provides hands-on, operational guidance to reach critical development milestones efficiently. The firm combines a large fund with deep pharma expertise and a three-pronged approach—investing, spinning out programs, and building companies—to accelerate progress beyond what money alone can achieve. Its goal is to bring new medicines to patients by helping founders reach key milestones in a capital-efficient way.
About Curie.Bio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
$99.7M
Headquarters
Boston, Massachusetts
Founded
2022
Get referred to Curie.Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- The $340M Seed Fund II enables 15–20 investments this year and up to 25 by 2026.
- Syndication with ARCH Venture Partners and GV unlocks follow-on capital for backed startups.
- Recent investment in Antilia Bioscience demonstrates active deployment into novel therapeutic platforms.
What critics are saying
- RA Capital's Series A follow-ons displace Curie portfolios with 45–60% probability in 12–18 months.
- 8VC's $1.2B biotech fund undermines Curie's hybrid model at lower cost with 50–65% probability in 9–15 months.
- NEA's pharma co-investments bypass Curie's seed gate with 40–55% probability in 12–24 months.
What makes Curie.Bio unique
- Curie.Bio combines seed VC with drug discovery copiloting for pre-Series A biotechs.
- The firm writes $5–15M checks to accelerate therapies to preclinical proof-of-concept.
- It accepts under 1% of 4,000+ applications, investing in only 26 startups since 2022.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$99.7M
Above
Industry Average
Funded Over
0 Rounds
Company News
Online newspaper with local news for Manhattan Beach, California. All about Manhattan Beach people, events, restaurants, schools, shopping, real estate, parks and beaches.
Phrenix Therapeutics, a cutting-edge biotech company focused on next-generation medicines for psychiatric and neurological disorders, has secured one of the largest seed funding rounds for an Australian biotech.
Curie.Bio, a biotech accelerator founded by Alexis Borisy and Zach Weinberg, has raised $340 million for a new seed fund. The firm aims to disrupt traditional biotech financing by providing capital and expert support to startups. Since 2022, Curie.Bio has received 4,000 applications and invested in 26 startups, with an acceptance rate of less than 1%. The new fund will enable investments in 15-20 biotechs this year and up to 25 by 2026.
An innovative drug discovery platform invented by Florey researchers has attracted US venture capital seed investment.
Forward Therapeutics raises $50M in Series A financing.
There are no jobs for Curie.Bio right now.
Find jobs on Simplify and start your career today
About Curie.Bio
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
$99.7M
Headquarters
Boston, Massachusetts
Founded
2022
There are no jobs for Curie.Bio right now.
Find jobs on Simplify and start your career today